Given that the abnormal activation of NLRP3 has been linked to various diseases, including neutrophilic asthma, Alzheimer’s disease, inflammatory bowel disease, and atherosclerosis, biopharmaceutical companies are now developing NLRP3 inhibitors as potential treatments for these conditions. The gene discussed is NLRP3; the disease is Alzheimer disease.